Page last updated: 2024-10-31

mexiletine and Neuralgia

mexiletine has been researched along with Neuralgia in 19 studies

Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.

Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.

Research Excerpts

ExcerptRelevanceReference
"To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing."9.11Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004)
"To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing."5.11Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004)
"Threshold tracking was used to measure multiple excitability indices (strength-duration time constant, rheobase, refractoriness, supernormality, and threshold electrotonus) in median motor axons of 20 patients with neuropathic pain or muscle cramping, before and 3 months after treatment with oral 300 mg mexiletine per day."5.11The effects of mexiletine on excitability properties of human median motor axons. ( Hattori, T; Hiraga, A; Kanai, K; Kuwabara, S; Misawa, S; Nakata, M; Ogawara, K; Tamura, N, 2005)
" In this study, we investigated the effects of M58373 on substance P release from sensory neurons in vitro and pain behaviors/responses in rats, compared with mexiletine."3.73Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. ( Akada, Y; Amano, K; Fukudome, Y; Itoh, M; Ogawa, S; Yamamoto, I; Yamasaki, F, 2006)
"Mechanisms of neuropathic pain relief from lidocaine therapy are yet to be understood."2.41Systemic lidocaine for neuropathic pain relief. ( Chen, LL; Mao, J, 2000)
"The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test."1.43Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016)
" Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain."1.34Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. ( Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Gonzalez, E; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Macintyre, DE; Martin, WJ; McGowan, E; Ok, H; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2007)
"Pretreatment with mexiletine, at doses of 3, 10 and 30 mg/kg, i."1.33Effect of mexiletine on vincristine-induced painful neuropathy in mice. ( Kamei, J; Nozaki, C; Saitoh, A, 2006)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (10.53)18.2507
2000's12 (63.16)29.6817
2010's3 (15.79)24.3611
2020's2 (10.53)2.80

Authors

AuthorsStudies
Hoyt, SB2
London, C2
Ok, H1
Gonzalez, E1
Duffy, JL2
Abbadie, C3
Dean, B1
Felix, JP2
Garcia, ML2
Jochnowitz, N2
Karanam, BV2
Li, X2
Lyons, KA2
McGowan, E2
Macintyre, DE1
Martin, WJ2
Priest, BT2
Smith, MM2
Tschirret-Guth, R1
Warren, VA2
Williams, BS1
Kaczorowski, GJ2
Parsons, WH1
Drizin, I1
Gregg, RJ1
Scanio, MJ1
Shi, L1
Gross, MF1
Atkinson, RN1
Thomas, JB1
Johnson, MS1
Carroll, WA1
Marron, BE1
Chapman, ML1
Liu, D1
Krambis, MJ1
Shieh, CC1
Zhang, X1
Hernandez, G1
Gauvin, DM1
Mikusa, JP1
Zhu, CZ1
Joshi, S1
Honore, P1
Marsh, KC1
Roeloffs, R1
Werness, S1
Krafte, DS1
Jarvis, MF1
Faltynek, CR1
Kort, ME1
Thomas-Fowlkes, BS1
Iolascon, G1
Barohn, RJ1
Gajewski, B1
Pasnoor, M1
Brown, A1
Herbelin, LL1
Kimminau, KS1
Mudaranthakam, DP1
Jawdat, O1
Dimachkie, MM1
Iyadurai, S1
Stino, A1
Kissel, J1
Pascuzzi, R1
Brannagan, T1
Wicklund, M1
Ahmed, A1
Walk, D1
Smith, G1
Quan, D1
Heitzman, D1
Tobon, A1
Ladha, S1
Wolfe, G1
Pulley, M1
Hayat, G1
Li, Y1
Thaisetthawatkul, P1
Lewis, R1
Biliciler, S1
Sharma, K1
Salajegheh, K1
Trivedi, J1
Mallonee, W1
Burns, T1
Jacoby, M1
Bril, V1
Vu, T1
Ramchandren, S1
Bazant, M1
Austin, S1
Karam, C1
Hussain, Y1
Kutz, C1
Twydell, P1
Scelsa, S1
Kushlaf, H1
Wymer, J1
Hehir, M1
Kolb, N1
Ralph, J1
Barboi, A1
Verma, N1
Ahmed, M1
Memon, A1
Saperstein, D1
Lou, JS1
Swenson, A1
Cash, T1
Matsuura, W1
Harada, S1
Tokuyama, S1
Weston, RM1
Subasinghe, KR1
Staikopoulos, V1
Jarrott, B1
Isose, S1
Misawa, S2
Sakurai, K1
Kanai, K2
Shibuya, K1
Sekiguchi, Y1
Nasu, S1
Noto, Y1
Fujimaki, Y1
Yokote, K1
Kuwabara, S2
Erichsen, HK1
Hao, JX1
Xu, XJ1
Blackburn-Munro, G1
Attal, N1
Rouaud, J1
Brasseur, L1
Chauvin, M1
Bouhassira, D1
Tamura, N1
Hiraga, A1
Ogawara, K1
Nakata, M1
Hattori, T1
Garry, EM1
Delaney, A1
Anderson, HA1
Sirinathsinghji, EC1
Clapp, RH1
Kinchington, PR1
Krah, DL1
Fleetwood-Walker, SM1
Kamei, J1
Nozaki, C1
Saitoh, A1
Akada, Y1
Ogawa, S1
Amano, K1
Fukudome, Y1
Yamasaki, F1
Itoh, M1
Yamamoto, I1
Ebell, MH1
Carroll, IR1
Kaplan, KM1
Mackey, SC1
Galer, BS1
Harle, J1
Rowbotham, MC1
Mao, J1
Chen, LL1
Tanelian, DL1
Brose, WG1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)[NCT02260388]Phase 4402 participants (Actual)Interventional2014-10-31Completed
Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267]Phase 329 participants (Actual)Interventional2014-08-01Completed
Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394]Phase 1/Phase 226 participants (Actual)Interventional2017-09-15Completed
Intravenous Lidocaine for Perioperative and Postoperative Analgesia[NCT03921567]Phase 4520 participants (Anticipated)Interventional2019-04-15Recruiting
Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271]5 participants (Actual)Interventional2013-05-31Terminated (stopped due to Due to limited population of research participants.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

PROMIS Fatigue Short Form v1.0 8a

"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks

InterventionT-Score (Mean)
Nortriptyline53.6
Duloxetine55.4
Pregabalin56.7
Mexiletine51.6

PROMIS Pain Interference Short Form v1.0 8a T Score

"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline56.4
Duloxetine56.5
Pregabalin60.0
Mexiletine54.5

PROMIS Sleep Disturbance Short Form v1.0 8a

"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline58.9
Duloxetine58.9
Pregabalin58.3
Mexiletine59.1

SF12 Health Composite Scores

"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks

,,,
InterventionNorm-Based Standardization Score (Mean)
Mental Component ScorePhysical Component Score
Duloxetine50.942.1
Mexiletine51.343.7
Nortriptyline51.042.8
Pregabalin47.240.0

The Cumulative Dose of Oxaliplatin

The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks

Interventionmg (Mean)
Placebo + FOLFOX1161.8
Lidocaine + FOLFOX1294.8

Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time

"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks

,
Interventionscore on a scale*days (Mean)
pain AUCunpleasantness AUC
Lidocaine + FOLFOX9.525.4
Placebo + FOLFOX16.433.1

Changes in NPSI Score.

Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks

,
Interventionscore on a scale (Median)
6 weeks visit12 weeks visitlast follow-up visit
Lidocaine + FOLFOX0013.5
Placebo + FOLFOX003.0

CIPN Score on EORTC QLQ-CIPN20

"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks

,
Interventionscore on a scale (Median)
1234-36 weeks
Lidocaine + FOLFOX437.0
Placebo + FOLFOX217.0

Visual Analog Scale (VAS) at Visit 3

Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3

Interventionunits on the VAS (Mean)
CRPS I Pain Subjects3.67

Reviews

3 reviews available for mexiletine and Neuralgia

ArticleYear
Is systemic administration of local anesthetic agents effective for relieving neuropathic pain? A Cochrane Review summary with commentary.
    NeuroRehabilitation, 2020, Volume: 47, Issue:2

    Topics: Anesthetics, Local; Humans; Lidocaine; Mexiletine; Neuralgia; Randomized Controlled Trials as Topic;

2020
Systemic lidocaine or mexiletine for neuropathic pain.
    American family physician, 2006, Jul-01, Volume: 74, Issue:1

    Topics: Administration, Oral; Anesthetics; Evidence-Based Medicine; Humans; Infusions, Intravenous; Lidocain

2006
Systemic lidocaine for neuropathic pain relief.
    Pain, 2000, Volume: 87, Issue:1

    Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel

2000
Systemic lidocaine for neuropathic pain relief.
    Pain, 2000, Volume: 87, Issue:1

    Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel

2000
Systemic lidocaine for neuropathic pain relief.
    Pain, 2000, Volume: 87, Issue:1

    Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel

2000
Systemic lidocaine for neuropathic pain relief.
    Pain, 2000, Volume: 87, Issue:1

    Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel

2000

Trials

4 trials available for mexiletine and Neuralgia

ArticleYear
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
    JAMA neurology, 2021, 01-01, Volume: 78, Issue:1

    Topics: Adult; Aged; Analgesics; Bayes Theorem; Comparative Effectiveness Research; Duloxetine Hydrochloride

2021
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
The effects of mexiletine on excitability properties of human median motor axons.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2005, Volume: 116, Issue:2

    Topics: Action Potentials; Administration, Oral; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Axons;

2005
Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.
    Journal of pain and symptom management, 1996, Volume: 12, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anesthetics, Local; Anti-Arrhythmia Agents; Double-Blind Method;

1996

Other Studies

12 other studies available for mexiletine and Neuralgia

ArticleYear
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
    Bioorganic & medicinal chemistry letters, 2007, Nov-15, Volume: 17, Issue:22

    Topics: Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Dogs; Drug Evaluation,

2007
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
    Bioorganic & medicinal chemistry, 2008, Jun-15, Volume: 16, Issue:12

    Topics: Analgesics, Non-Narcotic; Animals; Ether-A-Go-Go Potassium Channels; Furans; Humans; Male; Mice; Neu

2008
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
    Bioorganic & medicinal chemistry letters, 2013, Jun-15, Volume: 23, Issue:12

    Topics: Animals; Benzazepines; Disease Models, Animal; Neuralgia; Rats; Sodium Channel Blockers

2013
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:5

    Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico

2016
Design and assessment of a potent sodium channel blocking derivative of mexiletine for minimizing experimental neuropathic pain in several rat models.
    Neurochemical research, 2009, Volume: 34, Issue:10

    Topics: Analgesics; Animals; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Male; Mex

2009
Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2010, Volume: 121, Issue:5

    Topics: Adult; Aged; Axons; Electric Conductivity; Electrophysiological Phenomena; Female; Humans; Lidocaine

2010
A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain.
    European journal of pharmacology, 2003, Jan-05, Volume: 458, Issue:3

    Topics: Analgesics; Analysis of Variance; Anesthetics, Local; Animals; Disease Models, Animal; Dose-Response

2003
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
    Pain, 2005, Volume: 118, Issue:1-2

    Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani

2005
Effect of mexiletine on vincristine-induced painful neuropathy in mice.
    European journal of pharmacology, 2006, Apr-24, Volume: 536, Issue:1-2

    Topics: Animals; Arginine; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibi

2006
Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
    European journal of pharmacology, 2006, May-01, Volume: 536, Issue:3

    Topics: Analgesics; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Formaldehyde; Ganglia, Spina

2006
Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success.
    Journal of pain and symptom management, 2008, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Aged; Anesthetics, Local; Choice Behavior; Chronic Disease; Female; Humans; Kapla

2008
Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine.
    Anesthesiology, 1991, Volume: 74, Issue:5

    Topics: Adult; Aged; Carbamazepine; Female; Humans; Lidocaine; Male; Mexiletine; Neuralgia; Peripheral Nerve

1991